MIDDLE EAST HEALTHCARE COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.5 SAR | +1.46% |
|
+5.43% | -5.44% |
| May. 06 | Middle East Healthcare Posts Higher Q1 Net Profit, Revenue | MT |
| May. 05 | Middle East Healthcare Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With a 2024 P/E ratio at 30.35 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.28 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -5.44% | 2.02B | - | ||
| -25.47% | 15.13B | B+ | ||
| -1.80% | 11.77B | B | ||
| +6.18% | 10.36B | B+ | ||
| +26.57% | 8.54B | B | ||
| -6.29% | 7.42B | A- | ||
| +5.28% | 6.72B | B- | ||
| +8.59% | 6.32B | D | ||
| -2.79% | 4.3B | - | ||
| +9.97% | 4.21B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4009 Stock
- Ratings Middle East Healthcare Company
